Skip to main content
SNPX logo

Synaptogenix, Inc. (SNPX) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$24.55 +$0.29 (+1.20%) |CouncilSplit View · 53 · B
Vol: 11.5K|

Beta 1.30: the stock has moved about 30% more than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Synaptogenix, Inc. (SNPX) trades at $24.55. Synaptogenix, Inc. is a biopharmaceutical company focused on developing Bryostatin-1 for Alzheimer's disease and other neurodegenerative disorders. Sector: Healthcare.

Price as of · Last analyzed: Mar 17, 2026
Synaptogenix, Inc. is a biopharmaceutical company focused on developing Bryostatin-1 for Alzheimer's disease and other neurodegenerative disorders. Founded in 2012, it operates from New York City and has established licensing agreements with prestigious institutions.

Analyst Coverage for SNPX: SNPX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

Council Score · Weighted Average of 3 Disciplines
Split View 53/100 · B

SNPX: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated)Ray Dalio
Favorable read
Griffin-style lens (simulated)Ken Griffin
Favorable read
Simons-style lens (simulated)Jim Simons
Favorable read
Englander-style lens (simulated)Izzy Englander
Unfavorable read
Klarman-style lens (simulated)Seth Klarman
Neutral read
Moon AI lens (model)
Unfavorable read
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Neutral
Margin of Safety
Fairly Valued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →
The lenses are modelled on the published principles of the investors named. We are not affiliated with them, they have not endorsed this, and it is not their opinion of this stock.

Synaptogenix, Inc. (SNPX) Healthcare & Pipeline Overview

CEOAlan J. Tuchman MBA(FAAN)
Employees4
HeadquartersNew York City, US
IPO Year2020

Synaptogenix, Inc. is a biopharmaceutical firm specializing in innovative treatments for neurodegenerative diseases, with a primary focus on Bryostatin-1 for Alzheimer's disease, positioning itself within a rapidly evolving healthcare landscape.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 17, 2026

What Is the Investment Thesis for SNPX?

AI-written as of Mar 17, 2026 — figures and tone reflect the data available then, not today's score.

Synaptogenix, Inc. presents a unique investment thesis centered around its innovative drug candidate Bryostatin-1, which targets Alzheimer's disease and other cognitive disorders. With a market cap of $0.01 billion and a P/E ratio of -0.61, the company is in the early stages of development, which presents both risks and opportunities. The company’s partnerships with leading research institutions provide a solid foundation for its clinical programs, potentially accelerating development timelines. The global Alzheimer's disease therapeutics market is projected to grow significantly, creating a favorable environment for Synaptogenix's offerings. However, the company faces challenges such as the need for successful clinical trial outcomes and navigating regulatory approvals, which will be critical for its long-term success.

Based on FMP financials and quantitative analysis

SNPX Key Highlights

AI-written as of Mar 17, 2026 — figures and tone reflect the data available then, not today's score.

Market Cap of $0.01 billion reflects early-stage development in a high-growth sector.

  • P/E ratio of -0.61 indicates current losses typical for biotech firms in clinical stages.
  • Profit margin of -12829.9% highlights the significant R&D expenditures relative to revenue.
  • Gross margin of 100.0% suggests potential for high profitability upon successful commercialization.
  • Beta of 1.30 indicates higher volatility compared to the broader market, reflecting investor sentiment in biotech.

Who Are SNPX's Competitors?

SNPX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
AMTI Applied Molecular Transport Inc. $0.26 -3.13% $11.0M —
APGN Apexigen, Inc. $0.39 +8.48% $9.57M —
CYCC Cyclacel Pharmaceuticals, Inc. $6.37 -5.98% $10.6M —
GLS Gelesis Holdings, Inc. $0.16 0.00% $11.6M —
HURA TuHURA Biosciences, Inc. $1.70 +2.72% $105M —
NVO Novo Nordisk A/S $42.70 +6.24% $179B 92 5-pillar
VRTX Vertex Pharmaceuticals Incorporated $549.34 +3.50% $135B 95 5-pillar
REGN Regeneron Pharmaceuticals, Inc. $942.81 -3.14% $100B 95 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SNPX's Key Strengths?

Innovative drug candidate Bryostatin-1 with potential for significant market impact.

  • Strong academic partnerships enhancing research capabilities.
  • Focused approach on neurodegenerative diseases with high unmet needs.

What Are SNPX's Weaknesses?

Limited operational scale with only four employees.

  • Current financial losses typical for early-stage biotech companies.
  • Dependence on successful clinical trials for future growth.

What Could Drive SNPX Stock Higher?

Completion of clinical trials for Bryostatin-1, expected to provide data on efficacy and safety.

  • Development of additional therapeutic applications for Bryostatin-1 in other neurodegenerative conditions.
  • Potential new licensing agreements with additional research institutions to expand R&D capabilities.

What Are the Key Risks for SNPX?

High operational costs associated with research and development activities.

  • Regulatory hurdles that could delay product approvals and market entry.
  • Dependence on successful clinical trial outcomes to drive future growth.

What Are the Growth Opportunities for SNPX?

  • Synaptogenix's focus on Bryostatin-1 positions it to capture a share of this expanding market, particularly if clinical trials demonstrate efficacy and safety.
  • Growth opportunity 2: Synaptogenix is exploring the therapeutic applications of Bryostatin-1 for other neurodegenerative conditions such as multiple sclerosis and fragile X syndrome. The market for these conditions is also growing, with significant unmet needs, potentially allowing the company to diversify its product offerings and revenue streams.
  • Growth opportunity 3: The company’s strategic partnerships with leading academic institutions enhance its research capabilities and credibility. Collaborations with Stanford University and the Icahn School of Medicine at Mount Sinai may accelerate the development process and lead to innovative findings that can be commercialized.
  • Growth opportunity 4: As the biotechnology sector continues to attract investment, Synaptogenix may benefit from increased funding opportunities for its clinical programs. Successful fundraising efforts could provide the necessary capital to advance its drug candidates through clinical trials and towards commercialization.
  • Growth opportunity 5: The increasing focus on personalized medicine and targeted therapies in healthcare presents an opportunity for Synaptogenix to tailor its drug development strategies. By leveraging advancements in genomics and biotechnology, the company could enhance the effectiveness of its treatments and improve patient outcomes.

What Threats Does SNPX Face?

  • Intense competition from established biotech firms and new entrants.
  • Regulatory challenges and potential delays in drug approvals.
  • Market volatility impacting investor sentiment and funding availability.

What Are SNPX's Competitive Advantages?

  • Strong partnerships with prestigious academic institutions enhance credibility.
  • Focus on innovative therapies for unmet medical needs in neurodegenerative diseases.
  • Expertise in developing targeted treatments positions the company competitively.
  • Potential for high gross margins upon successful commercialization of therapies.
  • Early-stage focus allows for agility in research and development efforts.

What Does SNPX Do?

Founded in 2012 and headquartered in New York City, Synaptogenix, Inc. operates as a biopharmaceutical company dedicated to the development of innovative therapies for neurodegenerative diseases. The company’s primary focus is on Bryostatin-1, a drug candidate aimed at treating Alzheimer's disease. This drug is part of a broader platform that Synaptogenix is developing to address various cognitive dysfunctions and neurodegenerative conditions, including fragile X syndrome, multiple sclerosis, and Niemann-Pick type C disease. The company has forged significant licensing agreements with esteemed institutions such as Stanford University and the Icahn School of Medicine at Mount Sinai, which enhances its research capabilities and credibility in the biotechnology sector. With a small team of four employees, Synaptogenix is positioned to leverage its specialized knowledge and partnerships to advance its clinical development programs. The company is currently in the pre-clinical and clinical stages of development, working diligently to bring its innovative therapies to market. Synaptogenix's commitment to addressing unmet medical needs in neurodegenerative diseases underscores its potential for significant impact in the healthcare industry.

What Products and Services Does SNPX Offer?

  • Develops innovative biopharmaceuticals targeting neurodegenerative diseases.
  • Focuses on Bryostatin-1 for the treatment of Alzheimer's disease.
  • Explores therapeutic applications for other cognitive disorders.
  • Engages in licensing agreements with leading academic institutions.
  • Conducts pre-clinical and clinical development of drug candidates.
  • Aims to address unmet medical needs in the healthcare sector.

How Does SNPX Make Money?

  • Generates revenue through potential commercialization of drug candidates.
  • Engages in partnerships and licensing agreements with research institutions.
  • Focuses on attracting investment for clinical development and research.
  • Plans to leverage successful clinical trial outcomes for market entry.
  • Explores various therapeutic applications to diversify revenue streams.

What Industry Does SNPX Operate In?

The biotechnology industry is characterized by rapid innovation and significant investment in research and development, particularly in the realm of neurodegenerative diseases. The global market for Alzheimer's disease therapeutics is expected to grow substantially, driven by an aging population and increasing prevalence of cognitive disorders. Synaptogenix, Inc. is positioned within this dynamic landscape, focusing on novel therapies that address critical unmet needs. The competitive landscape includes several peers such as AMTI, APGN, CYCC, GLS, and HURA, each vying for market share in a sector where successful drug development can lead to substantial financial returns.

Who Are SNPX's Key Customers?

  • Healthcare providers seeking innovative treatments for patients.
  • Pharmaceutical companies interested in licensing agreements.
  • Research institutions collaborating on drug development.
  • Investors looking for opportunities in the biotechnology sector.
  • Patients and caregivers seeking effective therapies for neurodegenerative diseases.
Model self-rating on this text: 65% (not a measure of the evidence) Updated: Mar 17, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● Price 58 days old
  • ● No filing on record
  • ● No analyst coverage
FY2026 est

Forward Outlook

Wall Street analysts project Synaptogenix, Inc. revenue of about $41.7M for fiscal 2026, with EPS near $-7.03.

SNPX Financials

Bull Case vs Bear Case

Bull Case

  • Innovative drug candidate Bryostatin-1 with potential for significant market impact.
  • Strong academic partnerships enhancing research capabilities.
  • Focused approach on neurodegenerative diseases with high unmet needs.
  • Upcoming: Completion of clinical trials for Bryostatin-1, expected to provide data on efficacy and safety.

Bear Case

  • Limited operational scale with only four employees.
  • Current financial losses typical for early-stage biotech companies.
  • Dependence on successful clinical trials for future growth.
  • Ongoing: High operational costs associated with research and development activities.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

SNPX Latest News

No recent news available for SNPX.

SNPX Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SNPX.

Price Targets

Wall Street price target analysis for SNPX.

SNPX MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SNPX; grades run from A+ (80-100) to F (below 30).

Leadership: Alan J. Tuchman MBA(FAAN)

CEO

Alan J. Tuchman holds an MBA and is a Fellow of the American Academy of Nursing (FAAN). He has extensive experience in the healthcare sector, particularly in biopharmaceutical development and management. His leadership is marked by a commitment to advancing innovative therapies for neurodegenerative diseases.

Track Record: Under Alan J. Tuchman's leadership, Synaptogenix has established key partnerships with leading academic institutions, enhancing its research capabilities. His strategic vision has guided the company through its early development phases, focusing on innovative solutions for Alzheimer's disease and other cognitive disorders.

Synaptogenix, Inc. Healthcare Stock: Key Questions Answered

Is SNPX a good stock to buy?

Stock Expert AI does not rate SNPX buy, sell or hold. Synaptogenix, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the SNPX stock price today?

The last price recorded on this page for Synaptogenix, Inc. (SNPX) is $24.55, as of the Sep 21, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What do analysts say about SNPX stock?

Analysts generally view Synaptogenix, Inc. as a high-risk investment due to its early-stage development and current financial losses. The market is closely watching the progress of its clinical trials for Bryostatin-1, as successful outcomes could significantly enhance the company's valuation and market position.

What are the key factors to evaluate for SNPX?

Evaluate SNPX on fundamentals, analyst consensus, and risk factors. With a market cap of $0.01 billion and a P/E ratio of -0.61, the company is in the early stages of development, which presents both risks and opportunities. Not financial advice.

How frequently does SNPX data refresh on this page?

SNPX's price is the last quote we recorded, from the Sep 21, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven SNPX's recent stock price performance?

Synaptogenix, Inc. (SNPX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug candidate Bryostatin-1 with potential for significant market impact. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider SNPX overvalued or undervalued right now?

Synaptogenix, Inc. (SNPX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research SNPX before investing?

Before investing in Synaptogenix, Inc. (SNPX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • HURA · TuHURA Biosciences, Inc. · 28 /100
  • NVO · Novo Nordisk A/S · 92 /100
  • VRTX · Vertex Pharmaceuticals Incorporated · 95 /100

See all scored stocks →

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Data is based on current available information and may be subject to change.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives